Pharmaron Beijing Co. is specialised in the research, development and manufacturing of small molecule drugs, cell therapies and gene therapies. Net sales break down by activity as follows: - laboratory services (61.3%); - development and production of chemical processes and formulations (23.5%); - clinical research services (12.8%); - other (2.4%); Net sales are distributed geographically as follows: China (17.1%), Asia (2.6%), North America (64.2%), Europe (15.6%) and other (0.5%).

Employees

21,370

Sector

Biotechnology & Medical Research

Calendar

Dec. 18 - Extraordinary Shareholders Meeting

More about the company

Quotes

Date	Price	Change	Volume
25-12-12	29.91 ¥	+2.96%	34,843,000
25-12-11	29.05 ¥	-1.09%	15,089,080
25-12-10	29.37 ¥	+0.93%	15,110,500
25-12-09	29.10 ¥	-0.10%	19,176,720
25-12-08	29.13 ¥	-0.27%	13,887,180

End-of-day quote Shenzhen S.E., December 11, 2025

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

29.91CNY

Average target price

37.01CNY

Spread / Average Target

+23.74%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

End-of-day quote Shenzhen S.E. Other stock markets 2025-12-12			5-day change	1st Jan Change
29.91 ^CNY	+2.96%		+2.40%	+16.38%

Oct. 28	Pharmaron Beijing Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
Oct. 28	Pharmaron Beijing Co., Ltd. Announces Resignation of Tsang Kwan Hung Benson as Independent Non-Executive Director	CI

Capitalization	50.14B 7.11B 6.05B 5.66B 5.32B 9.8B 644B 10.7B 66.01B 25.6B 303B 26.66B 26.1B 1,107B	P/E ratio 2025 *	30.4x	P/E ratio 2026 *	24.8x
Enterprise value	53.76B 7.62B 6.49B 6.06B 5.7B 10.5B 690B 11.47B 70.77B 27.45B 325B 28.59B 27.99B 1,187B	EV / Sales 2025 *	3.82x	EV / Sales 2026 *	3.28x
Free-Float	48.56%	Yield 2025 *	0.69%	Yield 2026 *	0.85%

Oct. 28	Pharmaron Beijing Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
Oct. 28	Pharmaron Beijing Co., Ltd. Announces Resignation of Tsang Kwan Hung Benson as Independent Non-Executive Director	CI
Oct. 28	Pharmaron Beijing Q3 net profit up 42.5% Y/Y	RE
Oct. 27	Pharmaron Beijing Co., Ltd. agreed to acquire 3.08% stake in Wuxi Biortus Biosciences Co. Ltd. from Jiangyin Baiao Management Consulting Enterprise (Limited Partnership), Jiangyin Baisheng Management Consulting Center (Limited Partnership), Jiangyin Baichuang Management Consulting Center (Limited Partnership) and Jiangyin Baiying Management Consulting Center (Limited Partnership), Wu Jiaquan for CNY 27.2 million.	CI
Sep. 15	Pharmaron's Shaoxing Unit Passes US FDA On-Site Inspection	MT
Sep. 15	Pharmaron Beijing announces passing of U.S. FDA on-site inspection- by Pharmaron Shaoxing	RE
Aug. 25	Jefferies Adjusts Pharmaron Beijing's Price Target to HK$28 From HK$22, Keeps at Buy	MT
Aug. 22	Pharmaron Beijing H1 Profit Falls 37%, Revenue Rises 15%	MT
Aug. 22	Nomura Adjusts Pharmaron Beijing's Price Target to 34.62 Yuan From 33.75 Yuan, Keeps at Buy	MT
Aug. 22	Nomura Adjusts Pharmaron Beijing's Price Target to HK$26.63 From HK$25.86, Keeps at Buy	MT
Aug. 21	Pharmaron Beijing's H1 Profit Falls 37%	MT
Aug. 21	Pharmaron Beijing Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
Aug. 21	Pharmaron Beijing reports HY aggregate revenue of RMB6,441.0 million	RE

Aug. 25	Jefferies Adjusts Pharmaron Beijing's Price Target to HK$28 From HK$22, Keeps at Buy	MT
Aug. 22	Nomura Adjusts Pharmaron Beijing's Price Target to 34.62 Yuan From 33.75 Yuan, Keeps at Buy	MT
Aug. 22	Nomura Adjusts Pharmaron Beijing's Price Target to HK$26.63 From HK$25.86, Keeps at Buy	MT
Jul. 16	Nomura Adjusts Pharmaron Beijing's Price Target to 33.75 Yuan From 33.31 Yuan, Keeps at Buy	MT
Jul. 16	Nomura Adjusts Pharmaron Beijing's Price Target to HK$25.86 From HK$16.19, Keeps at Buy	MT

Pharmaron Beijing Co., Ltd. Stock

Equities

300759

CNE100003JW4

Biotechnology & Medical Research

Valuation: Pharmaron Beijing Co., Ltd.

Chart: Pharmaron Beijing Co., Ltd.

Latest news: Pharmaron Beijing Co., Ltd.

Analysts' recommendations: Pharmaron Beijing Co., Ltd.

Press Releases: Pharmaron Beijing Co., Ltd.

News in other languages: Pharmaron Beijing Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Pharmaron Beijing Co., Ltd.

ETFs: Pharmaron Beijing Co., Ltd.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Oct. 28	Pharmaron Acquires Biortus in China	BU
23-10-23	CORRECTION, Skye Bioscience to Host Virtual Investor Day on October 25, 2023, 'CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System'	AQ
23-03-30	Pharmaron's Liverpool UK Gene Therapy CDMO Commences Major Site Expansion Following UK Government Grant to Support GBP151m Investment	AQ
23-03-29	Pharmaron’s Liverpool UK Gene Therapy CDMO Commences Major Site Expansion Following UK Government Grant to Support £151m Investment	BU
22-05-24	Pharmaron Acquires Commercial API Manufacturing Facility in the United States	BU

24-01-29	Caída de cuchillos, Air Astana y extremismo
22-09-15	ANALYSEN DES TAGES von Dow Jones Newswires (15.09.2022)
21-07-14	Planète Bourse : La revue de presse du mercredi 14 juillet 2021

1 day	+2.96%
1 week	+2.40%
Current month	+3.32%
1 month	-4.99%
3 months	-11.38%
6 months	+20.41%
Current year	+16.38%

1 week	28.44	30.12
1 month	28.11	30.5
Current year	20.47	37.63
1 year	20.47	37.63
3 years	17.7	56.91
5 years	17.7	108.71
10 years	4.08	108.71

Manager	Title	Age	Since
Xiao Qiang Lou PSD	President	56	-
Bei Zheng PRN	Corporate Officer/Principal	58	2016-10-26
Bo Liang Lou CEO	Chief Executive Officer	61	2016-10-26

Director	Title	Age	Since
Bo Liang Lou CHM	Chairman	61	2016-10-26
Bei Zheng BRD	Director/Board Member	58	2016-10-26
Ke Xin Yang CHM	Chairman	63	2016-10-26

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
PHARMARON BEIJING CO., LTD.	+2.96%	+2.40%	+4.80%	-27.70%	7.11B
LONZA GROUP AG	+0.41%	-6.34%	-5.86%	+12.11%	45.43B
IQVIA HOLDINGS INC.	-1.65%	-1.59%	+11.65%	+3.76%	37.85B
BEONE MEDICINES AG	-0.55%	-1.19%	+77.90%	+52.49%	35.31B
CELLTRION, INC.	+0.05%	+1.91%	+5.47%	+16.56%	27.66B
MEDPACE HOLDINGS, INC.	-1.46%	+1.78%	+61.28%	+164.91%	15.72B
REVOLUTION MEDICINES, INC.	+0.52%	-0.90%	+75.34%	+225.18%	15.26B
ICON PUBLIC LIMITED COMPANY	-1.76%	+0.38%	-10.36%	-4.21%	14.25B
ASCENDIS PHARMA A/S	+4.88%	+7.29%	+69.72%	+81.46%	13.47B
IONIS PHARMACEUTICALS, INC.	+2.12%	-1.05%	+120.76%	+111.02%	13.09B
Average	+0.53%	+0.20%	+41.07%	+63.56%	22.51B
Weighted average by Cap.	+0.01%	-0.98%	+33.74%	+50.30%

	2025 *	2026 *
Net sales	14.08B 2B 1.7B 1.59B 1.49B 2.75B 181B 3B 18.53B 7.19B 85.18B 7.49B 7.33B 311B	16.06B 2.28B 1.94B 1.81B 1.7B 3.14B 206B 3.43B 21.14B 8.2B 97.16B 8.54B 8.36B 354B
Net income	1.72B 244M 208M 194M 183M 336M 22.1B 367M 2.27B 879M 10.42B 915M 896M 38.01B	2.18B 309M 263M 246M 231M 426M 27.96B 465M 2.87B 1.11B 13.18B 1.16B 1.13B 48.08B
Net Debt	3.62B 513M 437M 408M 384M 707M 46.47B 773M 4.76B 1.85B 21.9B 1.92B 1.88B 79.91B	2.5B 355M 302M 282M 265M 489M 32.12B 534M 3.29B 1.28B 15.14B 1.33B 1.3B 55.23B